LncRNAs act as prognostic and diagnostic biomarkers in renal cell carcinoma: a systematic review and meta-analysis

Abstract

We conducted a systematic review and meta-analysis to investigate the clinical values, including clinicopathology, prognosis, and diagnosis of different long non-coding RNAs (lncRNAs) in renal cell carcinoma (RCC). A total of 14 eligible studies, including 10 on clinicopathological features, 11 on prognosis, and 3 on diagnosis were identified. Results revealed that metastasis-associated lung adenocarcinoma transcript 1(MALAT1) expression was associated with tumor stage (odds ratio [OR], 3.46; 95% confidence interval [CI], 1.63-7.36; p=0.001). The high expression of MALAT1 could be considered a biomarker of the early detection of lymph node metastasis and predictor of poor survival in RCC patients, who likely manifested short overall survival (OS; hazard ratio [HR], 2.97; 95% CI, 1.68-5.28; p<0.001). For diagnostic value, the pooled result showed that lncRNA maintained a sensitivity of 0.89 and specificity of 0.91 in RCC diagnosis, The area under the curve of 0.94 (95% CI, 0.92-0.96) for lncRNA in RCC diagnosis also indicated a significant advantage over other biomarkers. Our systematic review and meta-analysis demonstrated that lncRNAs could be considered biomarkers to detect lymph node metastasis and distant metastasis in early stages. LncRNAs could function as potential prognostic markers in RCC. LncRNAs could also display high accuracy for RCC diagnosis.

Altered long non-coding RNAs predict worse outcome in osteosarcoma patients: evidence from a meta-analysis

“…The results allowed us to suggest that lncRNA(s) expression is correlated to osteosarcoma with a more aggressive behavior. A study meta-analyzed the associations between lncRNA-MALAT1 expression and clinicopatholoical characteristics corroborates our findings: MALAT1 level was demonstrated to be closely associated with clinical stage and lymph node metastasis in renal cell carcinoma [11]. Another investigation from Jing et al presented the similar results [26].…”

Altered long noncoding RNAs and survival outcomes in ovarian cancer

“…Likewise, they found that altered lncRNAs were associated with poor survival outcomes in renal cell carcinoma, osteosarcoma, and hepatocellular carcinoma. [ 48 – 50 ] Luo et al [ 51 ] also performed a meta-analysis to investigate the prognostic value of abnormally expressed lncRNAs in ovarian cancer. In their study, 2 studies using microarray data were included [ 29 , 31 ] ; however, we did not include any studies using microarray data.…”

Long non-coding RNAs in renal cell carcinoma: A systematic review and clinical implications

“…Moreover, lncRNAs are involved in cancer biology and have been listed into one of the hallmarks of cancer [ 33 , 34 ]. They are associated with oncogenesis and may serve as promising a new type of biomarkers for tumor diagnosis, prognosis, even in targeted gene therapy [ 19 , 35 , 36 ].…”